KR102540515B1 - 인터류킨-2-유도성 t-세포 키나제를 조절하기 위한 화합물 및 방법 - Google Patents
인터류킨-2-유도성 t-세포 키나제를 조절하기 위한 화합물 및 방법 Download PDFInfo
- Publication number
- KR102540515B1 KR102540515B1 KR1020197015471A KR20197015471A KR102540515B1 KR 102540515 B1 KR102540515 B1 KR 102540515B1 KR 1020197015471 A KR1020197015471 A KR 1020197015471A KR 20197015471 A KR20197015471 A KR 20197015471A KR 102540515 B1 KR102540515 B1 KR 102540515B1
- Authority
- KR
- South Korea
- Prior art keywords
- unsubstituted
- substituted
- membered
- independently
- delete delete
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662417083P | 2016-11-03 | 2016-11-03 | |
| US62/417,083 | 2016-11-03 | ||
| PCT/US2017/059871 WO2018089261A2 (en) | 2016-11-03 | 2017-11-03 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190089891A KR20190089891A (ko) | 2019-07-31 |
| KR102540515B1 true KR102540515B1 (ko) | 2023-06-05 |
Family
ID=62109599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197015471A Active KR102540515B1 (ko) | 2016-11-03 | 2017-11-03 | 인터류킨-2-유도성 t-세포 키나제를 조절하기 위한 화합물 및 방법 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11008314B2 (https=) |
| EP (1) | EP3534899B1 (https=) |
| JP (2) | JP7236996B2 (https=) |
| KR (1) | KR102540515B1 (https=) |
| CN (1) | CN110099684B (https=) |
| AU (1) | AU2017358901B2 (https=) |
| CA (1) | CA3042252C (https=) |
| DK (1) | DK3534899T3 (https=) |
| ES (1) | ES2926153T3 (https=) |
| IL (1) | IL266181B2 (https=) |
| MX (1) | MX392031B (https=) |
| PT (1) | PT3534899T (https=) |
| WO (1) | WO2018089261A2 (https=) |
| ZA (1) | ZA201903071B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| JP2018513853A (ja) | 2015-04-10 | 2018-05-31 | アラクセス ファーマ エルエルシー | 置換キナゾリン化合物およびその使用方法 |
| WO2017058807A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3356353A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| KR20180081596A (ko) | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| CN110099684B (zh) * | 2016-11-03 | 2022-11-11 | 科尔沃斯制药股份有限公司 | 用于调节白介素-2诱导性t细胞激酶的化合物和方法 |
| CN110382482A (zh) | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的杂-杂二环化合物及其使用方法 |
| WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
| AU2018271990A1 (en) | 2017-05-25 | 2019-12-12 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| MX2021000887A (es) | 2018-08-01 | 2021-03-31 | Araxes Pharma Llc | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. |
| WO2020086739A1 (en) * | 2018-10-24 | 2020-04-30 | Araxes Pharma Llc | 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1h-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of g12c mutant kras protein for inhibiting tumor metastasis |
| CN114845709B (zh) | 2019-11-05 | 2024-10-01 | 德米拉公司 | 用于治疗炎性病症的mrgprx2拮抗剂 |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| WO2021262636A2 (en) * | 2020-06-23 | 2021-12-30 | Dana-Farber Cancer Institute, Inc. | Compounds for targeted degradation of interleukin-2-inducible t-cell kinase and methods of use |
| CN114605404B (zh) * | 2022-03-23 | 2024-01-05 | 合肥美诺医药有限公司 | 一种新型含噻唑类化合物、中间体及其应用 |
| CN114621213B (zh) * | 2022-03-23 | 2023-12-08 | 合肥美诺医药有限公司 | 含噻唑类化合物及其中间体与应用 |
| KR20240169633A (ko) * | 2022-04-05 | 2024-12-03 | 코버스 파마슈티칼스, 인크. | Th1 세포 활성을 증가시키기 위한 itk 저해제 |
| WO2025085889A1 (en) * | 2023-10-20 | 2025-04-24 | Corvus Pharmaceuticals, Inc. | Interleukin-2-inducible t-cell kinase inhibitors to produce enhanced immune responses |
| WO2025171035A1 (en) * | 2024-02-06 | 2025-08-14 | Corvus Pharmaceuticals, Inc. | Itk inhibitors and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002050071A1 (en) * | 2000-12-21 | 2002-06-27 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of tec family tyrosine kinases |
| US20140011810A1 (en) | 2009-12-23 | 2014-01-09 | Gatekeeper Pharmaceuticals, Inc. | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith |
| WO2016079231A1 (en) | 2014-11-19 | 2016-05-26 | Hach Lange Gmbh | Control of wastewater treatment based on regulatory period |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0212101A (pt) | 2001-08-24 | 2004-08-24 | Pharmacia & Up John Company | 7-aza [2.2.1] biciclo-heptanos substituìdos com heteroarila para o tratamento de doenças |
| RU2006111093A (ru) * | 2003-09-06 | 2007-10-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы атр-связывающих кассетных транспортеров |
| CN101711238A (zh) * | 2007-06-11 | 2010-05-19 | 百时美施贵宝公司 | 1,3-二羟基取代的苯基酰胺葡糖激酶激活剂 |
| US20100113520A1 (en) * | 2008-11-05 | 2010-05-06 | Principia Biopharma, Inc. | Kinase knockdown via electrophilically enhanced inhibitors |
| US9649313B2 (en) | 2012-11-26 | 2017-05-16 | The University Of North Carolina At Chapel Hill | Use of ITK inhibitors for the treatment of cancer |
| CN105164112B (zh) * | 2013-01-31 | 2017-10-13 | 中国科学院上海药物研究所 | 酰胺类化合物及其制备方法、药物组合物和用途 |
| US10112957B2 (en) | 2014-10-22 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
| CN105884711A (zh) * | 2014-12-16 | 2016-08-24 | 中国药科大学 | 噻唑类化合物、其制备方法及其在制药中的用途 |
| EP3347018B1 (en) | 2015-09-09 | 2021-09-01 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| CN110099684B (zh) * | 2016-11-03 | 2022-11-11 | 科尔沃斯制药股份有限公司 | 用于调节白介素-2诱导性t细胞激酶的化合物和方法 |
-
2017
- 2017-11-03 CN CN201780079068.5A patent/CN110099684B/zh active Active
- 2017-11-03 ES ES17868729T patent/ES2926153T3/es active Active
- 2017-11-03 WO PCT/US2017/059871 patent/WO2018089261A2/en not_active Ceased
- 2017-11-03 MX MX2019005076A patent/MX392031B/es unknown
- 2017-11-03 CA CA3042252A patent/CA3042252C/en active Active
- 2017-11-03 AU AU2017358901A patent/AU2017358901B2/en active Active
- 2017-11-03 JP JP2019522993A patent/JP7236996B2/ja active Active
- 2017-11-03 KR KR1020197015471A patent/KR102540515B1/ko active Active
- 2017-11-03 US US16/346,360 patent/US11008314B2/en active Active
- 2017-11-03 DK DK17868729.9T patent/DK3534899T3/da active
- 2017-11-03 PT PT178687299T patent/PT3534899T/pt unknown
- 2017-11-03 IL IL266181A patent/IL266181B2/en unknown
- 2017-11-03 EP EP17868729.9A patent/EP3534899B1/en active Active
-
2019
- 2019-05-16 ZA ZA2019/03071A patent/ZA201903071B/en unknown
-
2021
- 2021-04-07 US US17/224,410 patent/US11897874B2/en active Active
-
2022
- 2022-11-18 JP JP2022184820A patent/JP2023029752A/ja active Pending
-
2024
- 2024-02-12 US US18/439,695 patent/US20240383884A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002050071A1 (en) * | 2000-12-21 | 2002-06-27 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of tec family tyrosine kinases |
| US20140011810A1 (en) | 2009-12-23 | 2014-01-09 | Gatekeeper Pharmaceuticals, Inc. | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith |
| WO2016079231A1 (en) | 2014-11-19 | 2016-05-26 | Hach Lange Gmbh | Control of wastewater treatment based on regulatory period |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017358901A1 (en) | 2019-05-30 |
| US20190375743A1 (en) | 2019-12-12 |
| JP2019536763A (ja) | 2019-12-19 |
| ZA201903071B (en) | 2021-09-29 |
| EP3534899A2 (en) | 2019-09-11 |
| IL266181B2 (en) | 2024-04-01 |
| CN110099684B (zh) | 2022-11-11 |
| KR20190089891A (ko) | 2019-07-31 |
| IL266181A (en) | 2019-06-30 |
| EP3534899A4 (en) | 2020-04-29 |
| JP7236996B2 (ja) | 2023-03-10 |
| CA3042252A1 (en) | 2018-05-17 |
| US11008314B2 (en) | 2021-05-18 |
| US20240383884A1 (en) | 2024-11-21 |
| MX392031B (es) | 2025-03-21 |
| AU2017358901B2 (en) | 2023-01-05 |
| US11897874B2 (en) | 2024-02-13 |
| EP3534899B1 (en) | 2022-06-01 |
| WO2018089261A3 (en) | 2018-08-02 |
| IL266181B1 (en) | 2023-12-01 |
| JP2023029752A (ja) | 2023-03-06 |
| CN110099684A (zh) | 2019-08-06 |
| WO2018089261A2 (en) | 2018-05-17 |
| ES2926153T3 (es) | 2022-10-24 |
| MX2019005076A (es) | 2019-11-12 |
| DK3534899T3 (da) | 2022-06-20 |
| PT3534899T (pt) | 2022-07-07 |
| US20220363676A1 (en) | 2022-11-17 |
| CA3042252C (en) | 2025-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102540515B1 (ko) | 인터류킨-2-유도성 t-세포 키나제를 조절하기 위한 화합물 및 방법 | |
| KR102416971B1 (ko) | 브루톤형 티로신 키나제를 조절하기 위한 화합물 및 방법 | |
| CN116490184B (zh) | 用于抑制egfr突变癌症的化合物及其药物用途 | |
| JP6346862B2 (ja) | オレキシンレセプターアンタゴニストとしての置換プロリン／ピペリジン | |
| BR112012011287A2 (pt) | compostos inibidores de cinase, sua formulação farmacêutica e seus usos | |
| CA3115900C (en) | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | |
| EP3703678A1 (en) | Novel agents targeting inhibitor of apoptosis proteins | |
| KR102800635B1 (ko) | 단백질 키나아제 저해 활성을 갖는 피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 | |
| HK40014009A (en) | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | |
| HK40014009B (en) | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | |
| WO2025194116A1 (en) | Pcsk9 inhibitors and uses thereof | |
| WO2025175019A1 (en) | Phd ligands and uses thereof | |
| WO2025193711A1 (en) | Peripherally restricted lpar1 antagonists and uses thereof | |
| HK1262897B (en) | Compounds and methods for modulating bruton's tyrosine kinase | |
| HK1262897A1 (en) | Compounds and methods for modulating bruton's tyrosine kinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20190529 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20201030 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20220830 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20230426 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20230601 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20230601 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |